Status | In progress |
Decision | Selected |
Process | STA Review |
ID number | 3778 |
Provisional Schedule
Expected publication | 08 June 2022 |
Project Team
Project lead | Thomas Feist |
Email enquiries
- If you have any queries please email TAteam1@nice.org.uk
External Assessment Group | School of Health and Related Research (ScHARR), University of Sheffield |
Stakeholders
Companies sponsors | Janssen |
Others | Department of Health and Social Care |
NHS England | |
Welsh Government | |
Patient carer groups | Lymphoma Action |
WMUK | |
Professional groups | Association of Cancer Physicians |
British Society for Haematology | |
Cancer Research UK | |
Royal College of Pathologists | |
Royal College of Physicians | |
Comparator companies | Janssen-Cilag |
General commentators | All Wales Therapeutic Toxicology Centre |
British National Formulary | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
06 May 2022 - 19 May 2022 | Final draft guidance |
21 January 2022 - 11 February 2022 | Draft guidance |
07 December 2021 | Committee meeting: 1 |
10 June 2021 | Invitation to participate |
19 March 2021 | In progress. Topic is in progress |
For further information on our processes and methods, please see our CHTE processes and methods manual